AvengeBio was a biotechnology company that is now permanently closed.

AvengeBio

Adarx is a technology company that specializes in developing advanced data analytics and artificial intelligence solutions for healthcare and life sciences. Their platform aims to accelerate drug discovery and development by providing insights through data integration, machine learning, and predictive modeling.

Adarx

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Inc

Candid Therapeutics focuses on revolutionizing treatment paradigms for autoimmune diseases.

Metric
Company Name	AvengeBio	Adarx	Amgen Inc	Candid Therapeutics
Symbol			AMGN
MSH ID	COM:AVENGEBIO	COM:ADARX	COM:AMGEN	COM:CANDIDRX
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Technology	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Healthcare Technology	Drug Manufacturers - General	Biotechnology
Country	US	US	US	US
Stage
Employee Count	11	53	26.70K
Website	avengebio.com	adarx.com	amgen.com	candidrx.com
LinkedIn		adarx-pharmaceuticals-inc
Founders

Metric
Market Cap	1.20B	158.00B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			28.19B
Revenue (LTM)
Revenue (NTM)
Gross Profit			19.74B
EBITDA			7.90B
Operating Income			7.90B
Net Income			6.72B
EPS			12.56
Diluted EPS			12.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	90.47	95.03
28-Day Growth Score	17.75	34.38
90-Day Growth Score	13.37	86.62
365-Day Growth Score	14.27	76.63

Metric
Gross Profit Margin			0.70
Operating Profit Margin			0.32
EBITDA Margin			0.28
Net Profit Margin			0.24
Return on Equity			1.03
Return on Assets			0.07
Return on Capital Employed			0.12

AVEN

COM:AVENGEBIO

AvengeBio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			22.81
P/B Ratio			22.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			6.11
EV Multiple			12.57

Metric
Days Sales Outstanding			83.59
Days Payables Outstanding			69.95
Days Inventory Outstanding			411.08
Operating Cycle			513.92
Cash Conversion Cycle			445.24
Asset Turnover			0.34

Metric
Operating Cash Flow			8.47B
Free Cash Flow			7.36B
Cash Flow to Debt			0.13
Operating Cash Flow/Sales			0.30
Free Cash Flow Yield			0.06

Metric
Cash & Equivalents			10.94B
Accounts Receivable			-1.01B
Inventory			9.52B
Goodwill			18.63B
Debt to Capitalization			0.93
Debt to Assets			0.67
Current Ratio			2.86
Quick Ratio			1.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.03
R&D to Revenue			0.17
SG&A to Revenue